Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer. The trial tests the company’s investigational therapy, zoldonrasib, alongside standard care as a first-line treatment for adults with non-squamous non-small cell lung cancer harboring the RAS G12D mutation. Read Also: Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow Phase 3 Study Design And Evaluation The trial compares zoldonrasib in combination with pembrolizumab and a platinum-based chemotherapy doublet against a placebo paired with the same pembrolizumab and chemotherapy regimen. Zoldonrasib acts as an investigational, RAS(ON) G12D-selective inhibitor designed to combat RAS-addicted cancers. Read Also: Check out Benzinga FDA Calendar here. Primary And Secondary Trial Endpoints Researchers set progression-free survival as the primary endpoint for the trial. Secondary endpoints track overall survival, objective response rate, duration of response, safety, tolerability, and patient-reported outcomes. Revolution Medicines operates as a global, commercial-stage oncology company dedicated to discovering, developing, and delivering innovative therapies for patients diagnosed with RAS-addicted malignancies. In April 2025, Revolution Medicines shared new clinical data for zoldonrasib (RMC-9805) as monotherapy in patients with KRAS G12D mutant non-small cell lung cancer (NSCLC). Zoldonrasib had a favorable mean dose intensity of 98%, and no dose-limiting toxicities were observed. Preliminary antitumor activity was assessed in 18 efficacy-evaluable patients with NSCLC at the 1200 mg QD dose. The objective response rate (confirmed or pending confirmation) was 61% (n=11), and the disease control rate was 89% (n=16). RVMD Price Action: Revolution Medicines shares were up 6.90% at $194.71 at the time of publication on Tuesday, according to Benzinga Pro data. Read Also: Morgan Stanley's Mike Wilson Says Market Correction Nearly Over, Sees S&P 500 Hitting 8,500 Photo: Shutterstock